drugset
drugset / Trial / NCT06418477

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

NCT06418477 ↗

Phase 2 Recruiting 20 enrolled Peking University People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.

Timeline

Start
2024-06-15
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bortezomib Small molecule 1.3 mg/m2 Subcutaneous
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Oral
Subject Daratumumab Monoclonal antibody 16 mg/kg Intravenous
Subject Daratumumab Monoclonal antibody 1800 mg Intravenous
Subject Dexamethasone Small molecule 20 mg —
Subject Dexamethasone Small molecule 40 mg —

Indications

monoclonal gammopathy